At the time of writing, Kura Oncology Inc [KURA] stock is trading at $21.08, up 4.05%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KURA shares have gain 5.98% over the last week, with a monthly amount glided 4.98%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on December 22, 2023, when Mizuho initiated its Buy rating and assigned the stock a price target of $26. Previously, BofA Securities started tracking the stock with Buy rating on August 11, 2023, and set its price target to $31. On July 27, 2023, Scotiabank initiated with a Sector Perform rating and assigned a price target of $10.50 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $31 on May 17, 2023. Stifel initiated its recommendation with a Buy and recommended $25 as its price target on January 31, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on July 12, 2022, and assigned it a price target of $30. In a note dated February 15, 2022, Jefferies initiated an Buy rating and provided a target price of $35 on this stock.
For the past year, the stock price of Kura Oncology Inc fluctuated between $7.41 and $24.17. Currently, Wall Street analysts expect the stock to reach $28.67 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $21.08 at the most recent close of the market. An investor can expect a potential return of 36.01% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -154.5%, Pretax Profit Margin comes in at -143.11%, and Net Profit Margin reading is -143.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.4 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.55 points at the first support level, and at 20.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.50, and for the 2nd resistance point, it is at 21.93.
Ratios To Look Out For
It is important to note that Kura Oncology Inc [NASDAQ:KURA] has a current ratio of 14.94. As well, the Quick Ratio is 14.94, while the Cash Ratio is 1.35.
Transactions by insiders
Recent insider trading involved Bair Teresa Brophy, Chief Legal Officer, that happened on May 20 ’24 when 2615.0 shares were sold. SVP, Finance & Accounting, DOYLE THOMAS JAMES completed a deal on Jan 29 ’24 to sell 2318.0 shares. Meanwhile, Chief Legal Officer Bair Teresa Brophy sold 2053.0 shares on Jan 29 ’24.
